Author(s): Carda, José Pedro ; Santos, Lurdes ; Mariz, José Mário ; Monteiro, Pedro ; Gonçalves, Humberto Miguel ; Raposo, João ; Silva, Maria Gomes da
Date: 2021
Persistent ID: https://hdl.handle.net/10316/101177
Origin: Estudo Geral - Universidade de Coimbra
Subject(s): B-cell malignancies; Bruton tyrosine kinase inhibitor; ibrutinib; recommendations
Ibrutinib, a potent inhibitor of the Bruton tyrosine kinase, has revolutionized the treatment of many B-cell malignancies. Ibrutinib has an established favorable toxicity profile with up to 8 years of experience in clinical trials; however, despite ibrutinib's favorable toxicity profile, dose reductions and treatment discontinuations are becoming more evident in clinical practice, particularly in the setting of specific clinical contexts and patient characteristics. This manuscript is set to provide practical recommendations on the management of patients treated with this agent in daily practice.
